Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) have announced preliminary results from the Phase 1b segment of the TACTIVE-U sub-study, which investigates the use of Vepdegestrant in conjunction with Abemaciclib for patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
The study revealed that administering Abemaciclib at 150 mg twice daily alongside the recommended Phase 3 monotherapy dose of 200 mg of Vepdegestrant once daily was both safe and well-tolerated by participants. Importantly, no significant drug-drug interactions were observed, and there were no clinically meaningful impacts on Abemaciclib exposure.
The combination therapy also showed promising results with a clinical benefit rate of 62.5% and an overall response rate of 26.7% in patients who had prior treatment with a CDK4/6 inhibitor.
In financial news, Arvinas’s stock has dropped by 1.75% to $24.64 on the Nasdaq, while Pfizer's shares are down 1.13%, currently trading at $25.81 on the New York Stock Exchange.
